Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Elixir Department: SOP for Limit Test for Chloride and Sulfates – V 2.0

Posted on By

Elixir Department: SOP for Limit Test for Chloride and Sulfates – V 2.0

Standard Operating Procedure for Limit Test for Chloride and Sulfates in Elixir Formulations

Department Elixir Department
SOP No. SOP/ELX/223/2025
Supersedes SOP/ELX/223/2022
Page No. Page 1 of 7
Issue Date 11/04/2025
Effective Date 15/04/2025
Review Date 11/04/2026

1. Purpose

To establish a standard procedure for conducting the limit test for chloride and sulfates in elixir formulations using visual comparison against standard solutions as per pharmacopeial guidelines.

2. Scope

This SOP is applicable to the Quality Control Department for testing the presence and permissible levels of chloride and sulfate impurities in raw materials and finished elixir products.

3. Responsibilities

  • QC Analyst:
    • Carry out the test, prepare reagents, and record observations.
  • QC Supervisor:
    • Ensure use of appropriate glassware and calibrated instruments.
  • QA Officer:
    • Review and approve test results before batch release.

4. Accountability

The QC Head is accountable for the accurate execution of the limit test. The QA Head is responsible for compliance with regulatory acceptance criteria and product quality assurance.

See also  Elixir Department: SOP for Preventive Maintenance of Filling Machines - V 2.0

5. Procedure

5.1 Limit Test for

Chloride
  1. Reagents: Nitric acid (dilute), silver nitrate solution (0.1N), standard chloride solution (e.g., 0.05845% NaCl equivalent to 0.035% Cl).
  2. Take 10 mL of the test solution in a Nessler cylinder.
  3. Add 1 mL of dilute nitric acid followed by 1 mL of silver nitrate solution.
  4. Mix and allow to stand for 5 minutes in diffused light.
  5. Simultaneously, prepare a standard solution using the same procedure.
  6. Compare the opalescence visually. The test passes if the opalescence in the sample is not greater than that of the standard.

5.2 Limit Test for Sulfates

  1. Reagents: Hydrochloric acid (dilute), barium chloride solution, standard sulfate solution (e.g., 0.181% K2SO4 equivalent to 0.1% SO42-).
  2. Take 10 mL of the test solution in a Nessler cylinder.
  3. Add 1 mL of dilute hydrochloric acid and 1 mL of 10% barium chloride solution.
  4. Stir with a glass rod and allow to stand for 10 minutes.
  5. Prepare a standard sulfate solution similarly.
  6. Compare turbidity. The test passes if the turbidity in the test sample is not more intense than that of the standard.

5.3 Notes

  • All glassware must be scrupulously clean and free from contaminants.
  • Do not perform the test under direct sunlight or harsh lighting.
  • If color interferes, decolorize using activated charcoal (if applicable).

5.4 Acceptance Criteria

  1. Chloride: Not more than 0.035% w/v (or as per specification).
  2. Sulfates: Not more than 0.1% w/v (or as per specification).

5.5 Documentation

  1. Record observations in the Chloride and Sulfate Limit Test Logbook (Annexure-1).
  2. Attach reagent preparation records and standard preparation references in the batch file.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QC: Quality Control
  • QA: Quality Assurance
  • w/v: Weight per Volume

7. Documents

  1. Chloride and Sulfate Limit Test Logbook (Annexure-1)
  2. Glassware and Reagent Preparation Records
  3. Batch Manufacturing Record (BMR)

8. References

  • USP General Chapter <221> – Inorganic Impurities: Tests for Chloride and Sulfate
  • IP / BP / Ph. Eur. Monographs for Limit Tests
  • 21 CFR Part 211.160 – Laboratory Controls

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Chloride and Sulfate Limit Test Logbook

Date Batch No. Chloride Result Sulfate Result Pass/Fail Tested By Verified By
11/04/2025 ELX-0425-041 Pass Pass Pass Rajesh Kumar Sunita Reddy

Revision History:

Revision Date Revision No. Revision Details Reason for Revision Approved By
01/01/2024 1.0 Initial SOP Release New SOP Creation QA Head
11/04/2025 2.0 Revised reagent quantities and test time Regulatory Alignment QA Head
Elixers V 2.0 Tags:Elixir colorants, Elixir dosage form, Elixir filtration techniques, Elixir flavoring agents, Elixir formulation, Elixir GMP compliance, Elixir manufacturing process, Elixir manufacturing SOPs, Elixir packaging requirements, Elixir pharmacopoeial standards, Elixir preparation methods, Elixir preservatives, Elixir production equipment, Elixir quality control, Elixir regulatory guidelines, Elixir shelf life, Elixir stability testing, Elixir sterilization methods, Elixir storage conditions, Elixir sweetening agents, Elixir viscosity modifiers, Hydroalcoholic solutions, Medicated elixirs, Non-medicated elixirs, Pharmaceutical elixirs

Post navigation

Previous Post: Analytical Method Development: SOP for Preparation of Linearity Data Table – V 2.0
Next Post: Maintaining Synchronization of SOPs With Related Documents and Policies

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version